FONTACTIV SUPPORT: CLINICAL EVIDENCE IN COLORECTAL PATIENTS PRESENTED AT ESPEN 2025

Clinical evidence presented at ESPEN 2025 supports the tolerance, acceptability and adherence to FontActiv^® Support in colorectal cancer patients before and after surgery

Laboratoires Grand Fontaine participated in the 47th ESPEN Congress, where new clinical evidence was presented on our oral nutritional supplement (ONS), FontActiv^® Support.

The poster, titled “A powdered nutritional formula effect on tolerance, acceptability, and adherence in patients with colorectal cancer pre- and post-surgery”, highlights the role of FontActiv^® Support in this clinical context.

Nutritional management is an essential component of care for patients with colorectal cancer (CRC), especially during the perioperative period, when maintaining adequate nutritional status can positively influence recovery, treatment tolerance, and overall outcomes¹.

The study evaluated the tolerance, acceptability, and adherence to FontActiv^® Support in patients with colorectal cancer before and after surgery.

Key findings include:

• High adherence rates both before and after surgery, reflecting the product’s good palatability.
• High overall acceptability, with the supplement’s eficacy being the most highly rated aspect.
• Adequate tolerance in both treatment phases, helping to meet the increased metabolic demands associated with surgery.

These results reinforce the value of FontActiv^® Support as a well-tolerated, acceptable, and effective oral nutritional supplement for patients with colorectal cancer.

Laboratoires Grand Fontaine remains committed to developing evidence-based nutritional solutions that support patient recovery and improve quality of life.

References:

1. Arends J. et al. ESPEN guidelines on nutrition in cancer patients. Clinical Nutrition. 2017;36(1):11–48.